Market Overview

UPDATE: Piper Jaffray Raises PT to $24 on NuVasive; Q4 Sets Stage for Outperformance

Share:
Related NUVA
The Market In 5 Minutes
GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update (Seeking Alpha)

Piper Jaffray maintained NuVasive (NASDAQ: NUVA) with an Overweight rating and raised the price target from $23.00 to $24.00.

Piper Jaffray noted, "Management delivered surprising upside on a nice bounce-back in revenues in 4Q12. However, the challenge for NuVasive going forward will be to string together 3-4 quarters of meeting or beating estimates and to drive growth into the double-digit range that management has framed out for investors as an aspirational long-term objective, which, based on management's comments, will require continued cooperation from the spine market in terms of further improvements in growth. … We do in fact expect continued improvements in spine market growth in 2013 and we remain buyers of NUVA at current levels."

NuVasive closed at $18.42 on Tuesday.

Latest Ratings for NUVA

DateFirmActionFromTo
Oct 2017BMO CapitalMaintainsOutperform
Oct 2017Wells FargoMaintainsOutperform
Oct 2017BarclaysMaintainsOverweight

View More Analyst Ratings for NUVA
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (NUVA)

View Comments and Join the Discussion!

Partner Center